Amgen Inc (AMGN · NASDAQ)
AMGN · MARKET VIEW
Market view · as of Sep 28, 2026
Revenue (TTM)
$38.09B
+9.5% YoY
Gross margin
71.9%
EPS (latest q)
$6.29
vs $5.60 est · beat
52-wk position
83.6%
-6.6% vs 52w high · -5.1% 1mo
Price (last ~year)
Amgen shares rose 2.1% to $414.61, leaving the stock up 15.4% over three months and 15.7% above its 200-day moving average, though still 6.6% below its 52-week high. The company beat estimates in all four of its most recent quarters, including June-quarter EPS of $6.29 versus $5.60 expected, with revenue of $10.05B and earnings growth of 64.9% year over year. Separately, Amgen sold its Deerfield, Illinois campus to a Mesirow entity for $151 million in a sale-leaseback, and reported positive Phase 3 results for dazodalibep in Sjögren's disease. Valuation metrics include a P/E of 25.77, EV/EBITDA of 14.92, and total debt of $57.30B against $13.99B in cash.
Valuation
- Market cap
- $224.15B
- P/E
- 25.77
- PEG
- 2.451
- P/B
- 18.78
- P/S
- 5.88
- EV/EBITDA
- 14.92
- Beta
- 0.426
- Analyst target
- $389.22
Quality & returns
- Gross margin
- 71.9%
- Operating margin
- 35.5%
- Profit margin
- 23.0%
- ROE
- 91.5%
- ROA
- 8.7%
Price movement
- Last
- $414.61
- 1-month
- -5.1%
- 3-month
- +15.4%
- RSI (14)
- 40
- vs SMA200
- +15.7%
- 52-wk position
- 83.6% -6.6% vs high
Quarterly trajectory
Revenue by quarter (oldest → newest)
| Quarter | Revenue | Op income | Net income | EBITDA |
|---|---|---|---|---|
| 2026-06-30 | $10.05B | $3.51B | $2.38B | $3.44B |
| 2026-03-31 | $8.62B | $2.67B | $1.82B | $3.86B |
| 2025-12-31 | $9.90B | $3.94B | $1.33B | $3.30B |
| 2025-09-30 | $9.56B | $2.53B | $3.22B | $5.91B |
Recent news
- Somewhat-Bullish Amgen (AMGN) Sells its Deerfield Campus for $151 Million and Leases it Back · 2026-09-27
- Neutral Amgen (AMGN) Sells its Deerfield Campus for $151 Million and Leases it Back · 2026-09-27
- Neutral Sarepta Therapeutics (SRPT) Falls As Patent Settlement Tests The Undervalued Narrative · 2026-09-26
- Bullish How Phase 3 Sjögren’s Results At Amgen (AMGN) Has Changed Its Investment Story · 2026-09-26
- Neutral Amgen’s Deerfield office campus sold to Mesirow for $151M in sale-leaseback deal · 2026-09-25
- Neutral Merck, Daiichi withdraw ifinatamab FDA application · 2026-09-25
Sources this view read
- fundamentals Company overview & valuation (Alpha Vantage OVERVIEW)
- filing Quarterly financial statements (Alpha Vantage INCOME/BALANCE/CASH)
- earnings Reported earnings history (Alpha Vantage EARNINGS)
- prices Adjusted daily prices (Alpha Vantage TIME_SERIES_DAILY_ADJUSTED)